seed finding
ZERO TO CANDIDATE


We work with clients to identify, build and acquire innovative new discovery projects


We call this seed finding.


Seed opportunities may be

  1. existing, early stage spin-outs

  2. opportunities to build new biotech projects from the seed research

‘ZERO TO CANDIDATE’ & BEYOND


We call the earliest stage of small molecule discovery projects ‘zero to candidate’. This essence captures commercially relevant research even if it is currently taking place in a university chemistry laboratory.


We apply the same rigorous approaches to assess the prospects of later stage third party projects
The same ‘zero to candidate’ assessment principles can be applied to biotherapeutics and non-conventional drugs such as stem cell therapies.
, such as those in the clinical phase. Implementation is through a specific set of methods that help identify, prioritise and build opportunities.


Our combination of analysis and action focuses on maximising the likelihood of success, through the objective selection of projects based on their own merits, rather than portfolio considerations.


This ability to assess and build projects according to stronger criteria enables us to stand apart from internal management capabilities as well as those consultancies that start from macro-economic estimates for clinical stage opportunities.


For seed finding we expect to find most opportunities in universities and early-stage biotech though our assessment covers all three main sectors and searches can be viewed as a continuum.

 

AVAILABILITY OF PROJECTS IN KEY SECTORS


1 Pharma : Later stage projects are sometimes de-prioritised or even terminated for managerial reasons presenting opportunities for observant purchasers.


2  Biotech : Promising biotech projects may flounder through lack of investment, particularly in the current economic environment, presenting investment opportunities


3 Time limited commercial Project : Place path finding money into promising discoveries to hit feasibility milestones


4 Universities : The scientific opportunities that form new biotechs typically originate here, yet even more projects fail to progress due to a combination of lack of expertise, time or funding necessary to convert a  promising scientific concept into a proper business opportunity. Many pharmaceutical companies are now looking at universities as an engine for innovation and this field is typically referred to as ‘translational research’ or ‘seed finding’. However it is important to meet the different expectations of both sides to make genuine progress.